Enzalutamide 40 MG
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer
Trial Timeline
Apr 13, 2018 → Nov 11, 2020
NCT ID
NCT03464201About Enzalutamide 40 MG
Enzalutamide 40 MG is a phase 2 stage product being developed by Astellas Pharma for Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03464201. Target conditions include Ovarian Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03464201 | Phase 2 | Completed |
Competing Products
20 competing products in Ovarian Cancer